GLP-1 weight-loss drugs likely to see value growth slowing down

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

India’s fast-growing glucagon-like peptide-1 (GLP-1) drug market is likely to witness a sharp rise in volumes but slower value growth as cheaper generics are set to enter the country after semaglutide goes off patent in March 2026, industry executives and doctors said.

 

While broader access could expand the patient base, experts also warn of higher therapy discontinuation rates. This comes as more users experience side effects or fail to sustain long-term treatment.

 

Two global drugmakers — Novo Nordisk and Eli Lilly — are currently vying for a larger share of India’s ₹1,109 crore anti-obesity market.

 

“The GLP-1 category is among